Skip to main content
See every side of every news story
Published • loading... • Updated

Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody Through a Standalone Company

  • Spruce Biosciences separated its CRHX-101 program into Adrenyx Biosciences, a wholly owned subsidiary focused on endocrinology.
  • Adrenyx is expected to be listed on Nasdaq during the first half of 2027.
  • Harbour BioMed expects to hold interests in both Spruce and Adrenyx after a planned stock distribution to Spruce shareholders.
  • Adrenyx plans to prepare CRHX-101 for regulatory review and begin clinical development after filing an application with the U.S. Food and Drug Administration.
Insights by Ground AI

25 Articles

The Logan BannerThe Logan Banner
+23 Reposted by 23 other sources
Center

Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 70% of the sources are Center
70% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Watauga Democrat broke the news in Calhoun, United States on Wednesday, November 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal